What You Should Know
- Continuous BTK‑inhibitor therapy can offer nearly decade‑long disease control for many CLL patients, with most treatment challenges occurring early and discontinuation rates dropping sharply after the first two years.
- Dr. Farrukh Awan, at UT Southwestern Medical Center, emphasizes that the choice between continuous and time‑limited therapy is highly individualized, shaped by side‑effect tolerance, other medical conditions, logistics, cost, and patient preference — “completely based on the discussion between the patient and the practicing physician.”
- Time‑limited regimens like venetoclax‑based combinations — and now all‑oral BTK + BCL‑2 inhibitor approaches — are increasingly favored, offering deep remissions and multi‑year treatment‑free intervals supported by long‑term trial data.
The Case for Continuous Therapy
“There is an argument that can be made that continuous therapy has served us really, really well for a long time,” Dr. Awan tells SurvivorNet.
Read More“Beyond the first two years, very few people stop treatment… the rate of discontinuation of treatment beyond two years goes down significantly,” he says.
“All of us have multiple patients nine, 10 plus years out who are doing well. They just take one or two pills a day, and they’re fine.”
The final 10-year analysis of the RESONATE-2 trial found no increasing trend in discontinuation rates over time, with discontinuations for side effects dropping from an overall rate of about a third of patients across the full study period to just single digits by years 9 and 10 — strong evidence that early years carry the most risk of stopping treatment, and things get steadier from there.
The Shift Toward Time-Limited Treatment
Despite that track record, Dr. Awan says his practice has moved in a different direction for most patients.
“Most people would like to stop treatment provided that the benefit of stopping is the same as the benefit of continuing treatment,” he explains. “For the most part, in our practice, we have moved away from continuous therapy, and we look at time-limited therapy.”
The idea behind time-limited treatment, Dr. Awan says, is straightforward.
“You get the disease into a very good remission, very deep remission, and then stop treatment. And then the patient will eventually have the disease come back after a few years. But hopefully that interval can be five, six, seven years.”
Long-term data on the leading fixed-duration regimen — venetoclax (Venclexta) combined with obinutuzumab (Gazyva) — supports this closely. In the final analysis of the CLL14 trial, patients received venetoclax plus obinutuzumab for one year. After approximately 6.4 years of follow-up, more than half had still not needed another CLL treatment.
Expert Resources for CLL Patients
- CLL Treatment: The Side Effects to Expect & Why Reporting All New Symptoms is Crucial
- An Oral Medicine for People With Relapsed CLL: Idelalisib
- BTK Inhibitors Play An Important Role In CLL Treatment & Management
- Chronic Lymphocytic Leukemia (CLL): How Can Jaypirca (Pirtobrutinib) Fit Into My Treatment Plan?
- Determining When CLL Treatment is Needed
- Do I Need A Stem Cell Transplant For CLL?
What Actually Goes Into the Treatment Decision Making
Dr. Awan says choosing between the two treatment approaches — and between specific drug combinations — comes down to a detailed conversation covering:
- Expected side effects and how a patient is likely to tolerate them
- Other medications the patient is taking and possible drug interactions
- Other medical conditions, particularly kidney, heart, or lung issues
- Logistics, including whether a patient can commit to regular infusion visits or prefers an all-pill regimen. “Sometimes it comes down to logistics,” Dr. Awan says. “Hey doc, I can’t come to the office once a month… that’s perfectly reasonable.”
- Cost and insurance considerations, including copays and prescription access
- Disease-specific factors, since, as Dr. Awan puts it, “the type of disease makes a huge difference” in which combination works best for a given patient.
Where the Field Is Heading
Dr. Awan says an “all-oral combination” is increasingly the preferred choice.
“Generally in the US, most people are leaning towards an all-oral combination of what we call BTK inhibitors and BCL-2 inhibitors… that has shown to have really, really good outcomes for our patients.”
In February 2026, the FDA approved acalabrutinib plus venetoclax as the first all-oral, fixed-duration combination for previously untreated CLL or small lymphocytic lymphoma. The main trial supporting the approval did not include patients with certain high-risk genetic changes, including a 17p deletion or TP53 mutation.
For younger, fit patients specifically, Dr. Awan says he sometimes considers going even further.
“For some young people, I might want to do three drugs because I want to get ahead of the disease. I want to get them into a deep, deep remission (having very little or no detectable disease) so that I won’t have to deal with it for 10 years.”
Overall, there’s no single “best” approach to treating CLL — continuous therapy and time-limited therapy are both backed by strong long-term data, and the right choice depends on a detailed, individualized conversation between patient and physician.
Dr. Awan adds that the decision is “completely based on the discussion between the patient and the practicing physician,” weighing side effects, other health conditions, lifestyle, and personal preference.
Questions to Ask Your Doctor
- Am I a better candidate for time-limited or continuous CLL treatment, and why?
- What side effects should I expect from each approach, and how will they be managed?
- Do my genetic test results or other disease characteristics affect which treatment is best for me?
- How often will I need blood tests or office visits?
- How long is the recommended treatment expected to control my CLL and what if it stops working?
- How might cost and insurance coverage affect my treatment options?
Learn more about SurvivorNet's rigorous medical review process.
